Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 8/20 | 0.61 |
| ▸ | MME | P08473 | 1/20 | 0.60 |
| ▸ | ACE | P12821 | 1/20 | 0.60 |
| ▸ | CPA1 | P15085 | 1/20 | 0.60 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.60 |
| ▸ | GPR34 | Q9UPC5 | 4/20 | 0.57 |
| ▸ | PPARA | Q07869 | 3/20 | 0.54 |
| ▸ | MMP9 | P14780 | 1/20 | 0.54 |
| ▸ | MMP8 | P22894 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.53 |
| ▸ | LTA4H | P09960 | 1/20 | 0.52 |
| ▸ | PPARD | Q03181 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5869558 | 1.00 | PPARG (0.61) | PPARGMMEACECPA1ACE2 | |
| SCHEMBL5869752 | 1.00 | PPARG (0.61) | PPARGMMEACECPA1ACE2 | |
| SCHEMBL5869597 | 0.89 | MAOB (0.56) | PPARGMMEACECPA1ACE2 | |
| SCHEMBL5869915 | 0.89 | MAOB (0.56) | PPARGMMEACECPA1ACE2 | |
| SCHEMBL6034328 | 0.88 | PPARG (0.65) | PPARGMMEACECPA1ACE2 | |
| SCHEMBL6034333 | 0.88 | PPARG (0.65) | PPARGMMEACECPA1ACE2 | |
| SCHEMBL5869623 | 0.88 | BCHE (0.54) | PPARGMMEACECPA1ACE2 | |
| SCHEMBL8249827 | 0.88 | MME (0.62) | PPARGMMEACECPA1ACE2 | |
| SCHEMBL5870487 | 0.88 | FFAR1 (0.54) | PPARGMME | |
| SCHEMBL5869658 | 0.88 | BCHE (0.54) | PPARGMMEACECPA1ACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7045532-B2 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-05-16 | — | — | US | disclosed |
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | ACE, ACE2, AGTR2 | PPARG 393/4885MME 11/4885ACE 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.